Status | Study |
Recruiting |
Study Name: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Condition: Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia My Date: 2016-12-01 Interventions: Drug: Bendamustine |
Completed |
Study Name: Mediastinal Grey Zone Lymphoma From the LYSA Condition: Mediastinal Grey Zone Lymphoma Date: 2016-11-04 |
Withdrawn |
Study Name: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Condition: Diffuse Large B Cell Lymphoma Mediastinal Large B-cell Lymphoma Date: 2015-09-24 Interventions: Drug: Brentuximab Brentuximab |
Recruiting |
Study Name: A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas Condition: CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma Date: 2013-11-20 Interventions: Drug: brentuximab vedotin |
Recruiting |
Study Name: Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Condition: Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Burkit Date: 2013-09-12 Interventions: Drug: CPX-351 Comparison of Different doses of drug |
Recruiting |
Study Name: Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Condition: CD20+, B-cell Lymphomas Mantle Cell Lymphoma Non-Mantle Ce Date: 2012-07-27 Interventions: Drug: Everolimus and Rituximab Everolimus: The initial dose of everolimus will be 2.5mg orally daily for |
Recruiting |
Study Name: Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Condition: Diffuse Large B-Cell Lymphoma (DLBCL) Primary Mediastinal Large B-cell Lymphoma Date: 1999-11-03 Interventions: Drug: EPOCH Combination chemot |